Olanzapine (Zyprexa)

A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.

Also Known As:

Networked: 5240 relevant articles (802 outcomes, 1546 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Tohen, Mauricio: 66 articles (11/2017 - 01/2002)
2.	Lieberman, Jeffrey A: 58 articles (01/2018 - 02/2002)
3.	Citrome, Leslie: 46 articles (03/2022 - 02/2002)
4.	Ascher-Svanum, Haya: 40 articles (08/2014 - 06/2004)
5.	Meltzer, Herbert Y: 39 articles (01/2021 - 08/2002)
6.	Kane, John M: 39 articles (06/2019 - 01/2003)
7.	Correll, Christoph U: 38 articles (06/2022 - 03/2008)
8.	Leucht, Stefan: 37 articles (09/2022 - 11/2005)
9.	Deng, Chao: 35 articles (01/2022 - 05/2007)
10.	Huang, Xu-Feng: 35 articles (08/2021 - 05/2007)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2020 - "Olanzapine was considered the most cost-effective drug for the first-line treatment of schizophrenia in Brazil. " 01/11/2013 - "The objective of this study was to confirm the efficacy of rapid-acting IM olanzapine 10 mg was greater than IM placebo in patients with exacerbation of schizophrenia with acute psychotic agitation by comparing changes from baseline to 2 hours after the first IM injection, as measured by the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) total score. " 05/01/2010 - "In a randomized, double-blind, multicentre, 6-week trial in adolescents aged 13-17 years with schizophrenia, the least squares mean reduction from baseline to 6 weeks in the Brief Psychiatric Rating Scale for Children (BPRS-C) total score (primary endpoint) was significantly greater with olanzapine than with placebo. " 05/01/2004 - "The purpose of the study was to assess the efficacy of high doses of olanzapine for treatment of the patient suffering from schizophrenia with predominance of positive symptoms. " 10/01/2003 - "The olanzapine-treated patients showed significant improvement in both the positive and negative symptoms of schizophrenia by the end of the study. "
2.	Weight Gain 01/01/2022 - "Among studies that reported weight as a continuous outcome, olanzapine was associated with significantly greater weight gain across all disorders (mean difference (MD) = 3.24 kg, 95% CI: 2.57-3.90 p = 0.001, N = 12 studies). " 11/01/2006 - "The olanzapine group had significantly greater improvements in secondary measures of severity and depressive symptoms and better study completion rates but experienced more weight gain." 02/01/2013 - "For olanzapine treated animals, weight gain was significantly greater in the minipump sample compared to both s.c. " 08/01/2009 - "Patients prescribed olanzapine had significantly greater weight gain from baseline (mean increase = 2.66 kg; 95% CI 2.35, 2.98) compared with those not prescribed olanzapine (mean increase = 1.85 kg; 95% CI 1.51, 2.19; p < 0.001). " 01/21/2009 - "Olanzapine either alone or as adjunctive treatment to mood stabilisers was associated with significantly greater weight gain than placebo. "
3.	Mania (Manias) 05/01/2006 - "Olanzapine is most effective for avoiding acute mania episodes. " 05/01/2010 - "In a randomized, double-blind, multicentre, 3-week trial in adolescents, aged 13-17 years, with manic or mixed episodes associated with bipolar I disorder, the mean reduction from baseline to 3 weeks in the Adolescent Structured Young Mania Rating Scale (YMRS) total score (primary endpoint) was significantly greater with olanzapine than with placebo. " 07/01/2019 - "There was a significant reduction in Young Mania Rating Scale and Clinical Global Impression-Bipolar scores over time in both groups, with a significantly higher reduction in the olanzapine group as shown by the group × time interaction effect. " 07/01/2015 - "Subgroup analyses showed that cannabis use was significantly associated with lower remission rates on the Hamilton Depression Rating Scale in females (n=139) and patients prescribed mood stabilizers alone (n=151), whereas in males (n=95) and patients prescribed olanzapine and/or a mood stabilizer (n=83), cannabis use was significantly associated with lower remission rates on the Young Mania Rating Scale. " 10/01/2007 - "The mean baseline-to-endpoint change in the Young Mania Rating Scale total score was significantly greater for patients receiving olanzapine relative to patients receiving placebo, and a greater proportion of olanzapine-treated patients met response and remission criteria (44.8% versus 18.5% and 35.2% versus 11.1%, respectively). "
4.	Psychotic Disorders (Schizoaffective Disorder) 09/01/2012 - "Postictal psychosis treated successfully with olanzapine." 09/01/2002 - "These findings did not demonstrate superior efficacy of olanzapine for treatment of dopamimetic-induced psychosis in PD. " 09/01/2004 - "These findings suggest that olanzapine itself may be effective for the treatment of monosymptomatic hypochondriacal psychosis. " 04/01/2001 - "Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. " 10/01/2011 - "Due to safety issues, olanzapine remains not useful for the treatment of psychosis. "
5.	Vomiting 11/01/2022 - "Olanzapine significantly improved complete control of vomiting in the delayed phase. " 11/10/2020 - "Olanzapine significantly improved CR rates for vomiting in children receiving the first cycle of HEC." 04/01/2018 - "Both doses of 10 and 5 mg olanzapine provided a significant improvement in delayed emesis. " 10/01/2023 - "The pooled analysis of this meta-analysis found that olanzapine had a higher complete response in all phases of emesis in the HEC group and only in the acute phase in HEC/MEC groups compared with the control group. " 11/01/2022 - "A significantly higher proportion of patients in the placebo group required rescue medications for vomiting compared with in the olanzapine group ( P =0.025). "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Risperidone (Risperdal Consta)
3.	Haloperidol (Haldol)
4.	Quetiapine Fumarate (Seroquel)
5.	Clozapine (Clozaril)
6.	Aripiprazole (Abilify)
7.	ziprasidone (Geodon)
8.	Valproic Acid (Depakote)
9.	Lithium
10.	Fluoxetine (Prozac)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Aftercare (After-Treatment)
4.	Injections
5.	Palliative Care (Palliative Therapy)